Vascular biology of atherosclerosis: overview and state of the art.

Our current understanding of the vascular biology of atherogenesis and its clinical manifestations suggests a pathophysiology that is much more complex than mere lipid storage. Recent advances support the current view of atherosclerosis as an inflammatory process that initiates and promotes lesion development to the point of acute thrombotic complications and clinical events. Inflammatory cells localize in early-stage atherosclerotic lesions, and recent basic research has established a causal relation between inflammatory mediators or cytokines, and the steps involved in progressing from local inflammation through plaque formation. Inhibition of the action of certain specific proinflammatory cytokines, such as CD40 ligand, interferes with atherogenesis in mice. Increased circulating levels of inflammatory markers indicate increased cardiovascular risk. Thus, the time has come to embrace inflammation as a common pathway for atherogenic risk factors and for providing new opportunities for therapeutic intervention.

[1]  P. Libby,et al.  Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.

[2]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[3]  M. Cybulsky,et al.  A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. , 2001, The Journal of clinical investigation.

[4]  W. Daniel,et al.  Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia , 2001, Circulation.

[5]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[6]  P. Libby,et al.  T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. , 1999, The American journal of pathology.

[7]  P. Libby,et al.  Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. , 1997, The American journal of pathology.

[8]  M. Daemen,et al.  Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Daemen,et al.  CD40-CD40L interactions in atherosclerosis. , 2002, Trends in cardiovascular medicine.

[10]  P. Libby,et al.  An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[11]  P. Libby,et al.  Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. , 1998, The Journal of clinical investigation.

[12]  P. Libby,et al.  Ligation of CD40 Activates Interleukin 1β-converting Enzyme (Caspase-1) Activity in Vascular Smooth Muscle and Endothelial Cells and Promotes Elaboration of Active Interleukin 1β* , 1997, The Journal of Biological Chemistry.

[13]  H. Florey,et al.  Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. , 1958, The Journal of pathology and bacteriology.

[14]  P. Libby,et al.  Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. , 1997, Circulation.

[15]  V. Ord,et al.  Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. , 1992, The American journal of pathology.

[16]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[17]  P. Libby,et al.  Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. , 1992, The American journal of pathology.

[18]  P. Libby,et al.  Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. , 1999, The Journal of clinical investigation.

[19]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[20]  R. Callard,et al.  Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin‐4 selectively induces expression of vascular cell adhesion molecule‐1 and P‐selectin resulting in preferential adhesion of lymphocytes , 2000, Immunology.

[21]  Michael Ginsberg,et al.  Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  James L. Young,et al.  Expression of Interleukin (IL)-18 and Functional IL-18 Receptor on Human Vascular Endothelial Cells, Smooth Muscle Cells, and Macrophages , 2002, The Journal of experimental medicine.

[23]  P. Libby,et al.  Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Ji Ming Wang,et al.  Chemokines as Molecular Targets for Therapeutic Intervention , 1999, Journal of Clinical Immunology.

[25]  P. Libby,et al.  Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.